Tech Company Financing Transactions
Vivace Therapeutics Funding Round
Vivace Therapeutics secured a $25 million Series B financing round on 6/29/2017. Backers included Cenova Capital, Canaan Partners and Mission Bay Capital.
Transaction Overview
Company Name
Announced On
6/29/2017
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Investors
Proceeds Purpose
Vivace is initially concentrating on inhibitors of the Hippo-YAP signaling pathway, which plays a crucial role in cell development, and genetic mutations of the pathway give rise to a variety of cancers.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2929 Campus Dr. 150
San Mateo, CA 94403
USA
San Mateo, CA 94403
USA
Phone
Undisclosed
Website
Email Address
Overview
At Vivace Therapeutics, we pursue our work with passion, driven by a conviction to help people fight cancer and live life to the fullest.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sofie Qiao
Chief Scientific Officer
Leonard Post
VP - Bus. Development
Tuomas Holmberg
VP - Operations
Amy Pfeiffer
Browse more venture capital transactions:
Prev: 6/29/2017: PatientPoint venture capital transaction
Next: 6/29/2017: MessageGears venture capital transaction
Share this article
Where The Data Comes From
We do our best to record funding rounds that are announced publicly. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs